InvestorsHub Logo
Followers 17
Posts 10875
Boards Moderated 0
Alias Born 03/11/2017

Re: None

Saturday, 01/13/2018 8:38:06 AM

Saturday, January 13, 2018 8:38:06 AM

Post# of 44784
Straightshot..There Is No Doubt That These Modified/Induced PLX-Cells Are Going To Change The Medical Landscape Forever. Pluristem Has Discovered Something That Is Beyond Words.

It May Just Be A Miracle Discovery... Thanks To Zami & Yaky And Their Incredibly Talented Pluristem... Powerhouse Research & Development Team. They Are Doing God's Work IMO ! 253,000 Woman Will Be Diagnosed With Breast Cancer This Year Alone In The United States.

Words Cannot Describe The Impact These New Induced PLX-Cells May Have On Millions Of Patients Across The Globe Every Single Year. IMO..These New Induced PLX-Cells Will Get Super-Fast Track Approval As The FDA Stated A Few Days Ago They Are Looking For A Way To Grant Approvals Early-On In A Clinical Study For Indications With Unmet Needs, When The Drug Shows Early Efficacy. See The BioCentury Link At The Very Bottom Of This Page.

The Sleeping Giant That Is Pluristem is About To Awake ! We Are Witnessing Medical History Right Before Our Eyes And I'm Very Proud To Be A Long-Time Pluristem Shareholder. Allo~[/b]


From: Pluristem's Cancer Study:


In Vitro Inhibition of Breast Cancer Cell Lines

"Of the six breast cancer cell lines examined in the 3D-spheroid screening assay, the two cell lines derived from TNBCs, MDA-MB-231 and HCC-1395, exhibited the strongest anti-proliferative response."


Note: Nude Mice Are Genetically Breed Not To Make T-Cells.


I Found This Paragraph Below To Be Very Intriguing.

"Finally, many of the cytokines secreted by the induced-ASCs are known to interact with cells of the immune system, especially T cells (which are lacking in nude mice), suggesting that the full potential of these human placental-derived ASCs on mitigating TNBC cancers may not yet have been fully realized."


This Study Is A Treasure Trove Of Incredible Information !


https://www.nature.com/articles/s41598-017-18428-1


BioCentury Link:

https://www.biocentury.com/bc-extra/politics-policy/2018-01-11/fda-releases-2018-policy-roadmap